## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence presented in the abstract, as supplied
- **Shared manuscript claim summary** The authors report a computational screening pipeline combining molecular docking, ADME, toxicity prediction, and molecular dynamics simulation to identify alkaloid inhibitors of the TBX3 transcription factor as potential anti-breast cancer agents. Five alkaloids (Jervine, Diflomotecan, Camptothecin, Vincamine, Anoniane) were selected as primary hits, and two (Jervine, Diflomotecan) were further supported by MM-GBSA and MD simulation as forming stable TBX3 complexes, leading the authors to propose these as lead candidates for drug development.
- **Visible evidence base** Abstract text only. No figures, tables, methods details, or numerical results are provided.
- **Missing materials affecting confidence** Full methods, docking scores, ADME and toxicity data, MD simulation parameters and trajectories, MM-GBSA values, structural coordinates, statistical analyses, and any experimental validation. None of these are available from the supplied material.

## Reviewer
- **Overall assessment** The abstract describes a plausible computational workflow for identifying TBX3-binding alkaloids, and the topic is of potential interest given TBX3's role in breast cancer. However, the evidence presented is entirely qualitative and lacks the quantitative detail needed to assess the validity of the docking, ADME, toxicity, and MD claims. The central conclusion that Jervine and Diflomotecan are viable drug leads is not established from the abstract alone, as no binding affinities, simulation stability metrics, or comparative benchmarks are reported. The work may have merit as a preliminary in silico screen, but the current presentation does not support the strength of the claims made.
- **Who would be interested in the results, and why** Computational biologists and medicinal chemists working on transcription factor targeting, particularly those focused on breast cancer drug discovery, would find this approach relevant. Researchers studying TBX3 biology or natural product-based inhibitor screening may also be interested, as the study proposes a pipeline that could be adapted to other targets. However, the lack of experimental validation limits appeal to a broader translational audience.
- **Major strengths** The study addresses a clinically relevant problem, namely drug resistance in breast cancer, by targeting a transcription factor with established oncogenic roles. The use of a multi-step computational funnel (docking, ADME, toxicity, MD, MM-GBSA) is a reasonable strategy to prioritize candidates. The selection of alkaloids as a chemical class is a defensible choice given their historical success as bioactive compounds.
- **Major Concerns**
  - **Concern ID** R1-M1
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Technical soundness
  - **Claim pointer** The abstract claims that five ligands were "primarily confirmed as potential inhibitors" and that Jervine and Diflomotecan "formed the stable complexes with TBX3."
  - **Evidence pointer** Abstract text, location not provided
  - **Concern** No quantitative data are provided to support the docking results, such as binding energy scores, RMSD values, or comparison to known inhibitors or decoys. The term "confirmed" is inappropriate for computational predictions without experimental validation. Similarly, the MD and MM-GBSA claims lack any numerical metrics (e.g., RMSD stability, binding free energy values, standard deviations) that would allow a reader to assess complex stability.
  - **Why it matters** The core conclusion rests on the stability and affinity of the TBX3-ligand complexes. Without these numbers, the claims are unverifiable and the prioritization of Jervine and Diflomotecan over the other three hits cannot be justified. This is a fundamental gap in the evidence chain.
  - **Resolution test** Provide docking scores for all five compounds, MD simulation stability metrics (e.g., RMSD, RMSF, radius of gyration) over time, and MM-GBSA binding free energies with error estimates. Ideally, include a positive control or benchmark against a known TBX3 binder to contextualize the results.
  - **Concern ID** R1-M2
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Scientific importance
  - **Claim pointer** The abstract implies that these alkaloids could be "introduced into the drug development pipeline" as leads against breast cancer.
  - **Evidence pointer** Abstract text, location not provided
  - **Concern** The leap from computational screening to drug development candidacy is unsupported. No experimental data (e.g., cell-based assays, target engagement, selectivity against other T-box family members) are presented or referenced. The abstract does not address whether TBX3 inhibition by these compounds would have functional consequences in breast cancer cells, nor does it discuss potential off-target effects.
  - **Why it matters** Computational predictions alone are insufficient to establish therapeutic potential. The claim of drug pipeline readiness overstates the significance of the findings and could mislead readers about the maturity of the work.
  - **Resolution test** Add experimental validation, such as TBX3 binding assays (e.g., SPR, ITC), cellular assays measuring TBX3 transcriptional activity, and selectivity profiling against related T-box proteins. At minimum, temper the language to describe these as preliminary computational hits requiring further validation.
  - **Concern ID** R1-M3
  - **Severity** Major
  - **Blocking** No
  - **Axis** Interdisciplinary readership
  - **Claim pointer** The abstract states that ADME and toxicity analysis showed "no toxicity effects" for the five compounds.
  - **Evidence pointer** Abstract text, location not provided
  - **Concern** The claim of "no toxicity effects" is presented as a binary outcome without specifying which toxicity endpoints were assessed (e.g., hepatotoxicity, cardiotoxicity, mutagenicity) or which computational tools were used. ADME predictions are inherently uncertain and depend heavily on the software and parameters chosen.
  - **Why it matters** For a broad readership, including experimental biologists and clinicians, the toxicity claim may be interpreted as a stronger safety statement than is warranted. This could influence decisions about pursuing these compounds.
  - **Resolution test** Specify the ADME and toxicity prediction tools, list the endpoints evaluated, and report the raw predictions for each compound. Acknowledge the limitations of computational toxicity prediction and avoid absolute language.
- **Minor Comments**
  - **Concern ID** R1-m1
  - **Severity** Minor
  - **Axis** Readability for nonspecialists
  - **Affected element** Background description
  - **Evidence pointer** Abstract text, location not provided
  - **Issue** The opening sentences on TBX3 biology are dense and assume familiarity with terms like "senescence shunt" and "anoikis," which are not explained.
  - **Required correction** Briefly define these terms or rephrase to make the relevance to cancer biology accessible to a broader audience.
  - **Concern ID** R1-m2
  - **Severity** Minor
  - **Axis** Technical soundness
  - **Affected element** Compound selection rationale
  - **Evidence pointer** Abstract text, location not provided
  - **Issue** The abstract does not explain why these specific alkaloids were chosen for screening, nor how the initial compound library was assembled.
  - **Required correction** Add a sentence describing the source or rationale for the alkaloid set, such as structural diversity, known bioactivity, or natural product databases.
  - **Concern ID** R1-m3
  - **Severity** Minor
  - **Axis** Scientific importance
  - **Affected element** Conclusion framing
  - **Evidence pointer** Abstract text, location not provided
  - **Issue** The phrase "it makes it obvious" is overly assertive for computational findings and detracts from the scientific tone.
  - **Required correction** Replace with a more measured statement, such as "suggesting that these compounds warrant further investigation."
- **Technical failings that need to be addressed before the case is established** R1-M1 and R1-M2 are blocking. The absence of quantitative docking, MD, and MM-GBSA data means the central claims of binding and stability cannot be evaluated. The lack of experimental validation or clear acknowledgment of the computational-only nature of the study undermines the drug development conclusion.
- **Assessment against Nature-style criteria**  
  Originality: The application of a computational screen to TBX3 is somewhat novel, as TBX3 is less commonly targeted than kinases or receptors, but the methods themselves are standard and do not introduce new techniques.  
  Scientific importance: The potential to address drug resistance in breast cancer is significant, but the current evidence does not demonstrate that these compounds would have therapeutic impact, limiting the importance of the findings as presented.  
  Interdisciplinary readership: The topic bridges computational chemistry and cancer biology, which could attract a broad audience, but the abstract lacks the detail needed for either community to fully engage.  
  Technical soundness: Not assessable from the abstract due to missing quantitative data. The workflow is plausible but unverified.  
  Readability for nonspecialists: The abstract is partially accessible but includes jargon and overclaims that reduce clarity.
- **Recommendation posture** Currently not established from the provided evidence. The computational approach is reasonable, but the abstract lacks the quantitative and experimental support needed to substantiate the claims. I would be supportive if the full manuscript provides docking scores, MD stability metrics, MM-GBSA values, and a clear statement of limitations, with language revised to reflect the preliminary nature of the findings.

## Risk / unsupported claims
- The claim that five ligands were "confirmed" as potential inhibitors is unsupported without quantitative docking data or experimental validation.
- The claim that Jervine and Diflomotecan formed "stable complexes" is unsupported without MD trajectory metrics or MM-GBSA values.
- The claim of "no toxicity effects" is unsupported without specifying the prediction tools and endpoints used.
- The proposal that these compounds can be "introduced into the drug development pipeline" is unsupported without any experimental evidence of functional activity or selectivity.
- The overall implication that this computational screen directly addresses drug resistance in breast cancer is not substantiated, as no link between TBX3 inhibition and resistance reversal is demonstrated.